Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ampio Pharmaceutical (AMPE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 37,185
  • Shares Outstanding, K 68,230
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,160 K
  • 36-Month Beta 0.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.27
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.16
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/01/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.47 +17.20%
on 07/11/17
0.62 -12.10%
on 06/23/17
-0.06 (-9.17%)
since 06/21/17
3-Month
0.47 +17.20%
on 07/11/17
1.04 -47.60%
on 05/08/17
-0.01 (-2.68%)
since 04/21/17
52-Week
0.47 +17.20%
on 07/11/17
1.14 -52.19%
on 12/27/16
-0.44 (-44.95%)
since 07/21/16

Most Recent Stories

More News
Ampio Injects First Patient in Final Pivotal Clinical Trial for Ampion(TM) BLA

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) initiates dosing in the AP-003-C, Phase 3, single injection Ampion(TM) study. This study addresses the "unmet medical need" in Kellgren-Lawrence (KL) grade...

AMPE : 0.55 (unch)
Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ("Ampio") today announced that it has closed its previously announced registered direct offering of 10,990,245 shares of common stock and warrants to purchase...

AMPE : 0.55 (unch)
Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has entered into a securities purchase agreement with investors providing for the registered sale of approximately $6.3 million of shares...

AMPE : 0.55 (unch)
Ampio Initiates Pivotal Trial of Ampion(TM)

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces initiation of a single injection study to meet the "unmet medical need" of treating the severe pain and loss of function associated with Kellgren-Lawrence...

AMPE : 0.55 (unch)
Ampio Pharmaceuticals Amends Warrant Agreement

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), a leader in the development of Ampion(TM), a low molecular weight fraction of human serum albumin with anti-inflammatory properties, announced that it entered...

AMPE : 0.55 (unch)
Update - Ampio Pharmaceuticals Provides Corporate Update

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), a leader in the development of Ampion(TM), a low molecular weight fraction of human serum albumin with anti-inflammatory properties, today announced that it...

AMPE : 0.55 (unch)
Ampio Pharmaceuticals Provides Corporate Update

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), a leader in the development of Ampion(TM), a low molecular weight fraction of human serum albumin with anti-inflammatory properties, announced an update of...

AMPE : 0.55 (unch)
Ampio Hosting Conference Call Tuesday, March 7, 4:30pm EST

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) will host an investor conference call Tuesday, March 7th at 4:30 pm EST. Participants are invited to dial-in using the instructions as listed below.

AMPE : 0.55 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company include Optina, an oral drug for the treatment of diabetic retinopathy and macular edema; and Vasaloc,...

See More

Support & Resistance

2nd Resistance Point 0.56
1st Resistance Point 0.55
Last Price 0.55
1st Support Level 0.53
2nd Support Level 0.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.